Q-Pad for HbA1c

About Qvin

Qvin is a San Francisco-based diagnostics company founded in 2018 that is commercializing a novel diagnostic platform centered on menstrual blood. The company's core innovation is the FDA-cleared Q-Pad, a collection device that enables the measurement of validated biomarkers (e.g., HbA1c, TSH, AMH) from menstrual effluent, correlating strongly with venous blood. By transforming a routine biological process into a diagnostic tool, Qvin seeks to revolutionize women's health research, improve early disease detection for conditions like diabetes and endometriosis, and create a more patient-centric, accessible testing paradigm. The company operates as a private, likely pre-revenue entity focused on research collaborations and future product commercialization.

Therapeutic Areas

Other Diabetes Monitoring Drugs